These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2480396)

  • 1. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Field trial of the early detection in patients with ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Kouda M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1743-9. PubMed ID: 2480393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
    Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Field trial for the early detection of patients with ovarian cancer].
    Kobayashi H; Terao T
    Rinsho Byori; 1992 Feb; 40(2):139-45. PubMed ID: 1374818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
    Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
    Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers of ovarian cancer].
    Nozawa S
    Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
    Chen DX; Li FQ
    Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating mucins as tumor markers in ovarian cancer (review).
    Devine PL; McGuckin MA; Ward BG
    Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
    Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
    Wu L; Sun J; Wang X
    Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer].
    Kimura E; Kobayashi S; Terashima Y
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2443-50. PubMed ID: 2260879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.